{"id":"W4283453063","doi":"10.1016/j.jtho.2022.05.016","title":"Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; Merck Sharp and Dohme; Genentech; Eisai; G1 Therapeutics; Puma Biotechnology; Yuhan; BeiGene; Mirati Therapeutics; Clovis Oncology; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; Takeda Pharmaceutical Company; AbbVie; Teva Pharmaceutical Industries; Boehringer Ingelheim Japan; Merck KGaA; Daiichi Sankyo Europe; National Cancer Institute; Bayer; Gilead Sciences; Roche; Novartis; Mesothelioma Applied Research Foundation; GlaxoSmithKline; Canadian Asian Studies Association; AstraZeneca; Ono Pharmaceutical; U.S. Department of Defense; Eli Lilly and Company; Bristol-Myers Squibb; Kyowa Hakko Kirin; Sanofi; Amgen; Boehringer Ingelheim; Pfizer","keywords":"Atezolizumab; Medicine; Placebo; Maintenance therapy; Hazard ratio; Internal medicine; Oncology; Carboplatin; Population; Chemotherapy; Cancer; Confidence interval; Immunotherapy; Pembrolizumab; Pathology; Cisplatin","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005774095,0.0002796196,0.0005208538,0.000326088,0.000248771,0.000522415,0.0002639921,0.0003626995,0.001676621],"category_scores_gemma":[0.001630844,0.0001296203,0.001036464,0.0005486437,0.0001586226,0.0003663024,0.0002831632,0.0003659223,0.0002478616],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003626423,"about_ca_system_score_gemma":0.0005414757,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001211172,"about_ca_topic_score_gemma":0.00146017,"domain_scores_codex":[0.9996516,0.0001330452,0.00003617446,0.00006381414,0.00005768943,0.00005768811],"domain_scores_gemma":[0.9990222,0.0003329153,0.0002667297,0.0001078296,0.00009813431,0.0001721398],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02776955,0.001095103,0.9258184,0.0001690235,0.0009756308,0.001942647,0.0001782666,0.000365484,0.009454758,0.00007704549,0.001452211,0.03070199],"study_design_scores_gemma":[0.0007038089,0.009634566,0.9828828,0.0000159935,0.0006930612,0.002475128,0.0002160467,0.0005217077,0.001199063,0.00006405236,0.001578016,0.00001569805],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978682,0.0004724916,0.00014859,0.000123667,0.00001291192,0.00005161131,0.0008490995,0.000009817732,0.0004635453],"genre_scores_gemma":[0.9968285,0.0002068062,0.0003052119,0.0001425639,0.00007987436,0.00004589914,0.001973087,0.000005453338,0.0004125966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001676621,"threshold_uncertainty_score":0.005608857,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02566415558250009,"score_gpt":0.377302734165158,"score_spread":0.351638578582658,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}